Ligand Pharmaceuticals | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.